Cartesian Therapeutics (RNAC) Non-Current Deferred Tax Liability (2022 - 2026)

Cartesian Therapeutics (RNAC) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 56.95% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 56.95% YoY), while the FY2025 annual figure was $6.9 million, down 56.95% from the prior year.
• Non-Current Deferred Tax Liability steadied at $6.9 million in Q1 2026 per RNAC's latest filing, from $6.9 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $44.0 million in Q4 2023 and bottomed at $3.3 million in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $15.8 million across 5 years, with a median of $15.9 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability jumped 1252.47% — and 2024, when it plunged 63.34%.
• Cartesian Therapeutics' Non-Current Deferred Tax Liability stood at $3.3 million in 2022, then surged by 1252.47% to $44.0 million in 2023, then slumped by 63.34% to $16.1 million in 2024, then slumped by 56.95% to $6.9 million in 2025, then changed by 0.0% to $6.9 million in 2026.
• Business Quant data shows RNAC's Non-Current Deferred Tax Liability at $6.9 million in Q1 2026, $6.9 million in Q4 2025, and $16.1 million in Q3 2025.